Shots: The EC approval is based on a P-III QUAZAR AML-001 study assessing Onureg (300mg, qd) vs PBO + BSC for 14days of a 28-day cycle in patients aged ≥55yrs. […]readmore
Tags : Onureg
Shots: The CHMP has recommended the approval of Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L treatment for unresectable MPM and is based P-III CheckMate -743 trial that met its 1EPs […]readmore
The US FDA has approved 6 NDAs in Sept 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) […]readmore
Shots: The approval is based on P-III QUAZAR AML-001 study assessing Onureg (300 mg, PO) vs PBO for 14 days of a 28-day cycle + BSC in a ratio (1:1) in 472 […]readmore